PRMT1 mediated methylation of YBX1 promotes tumorigenicity of glioblastoma stem cells

Technical Summary: PRMT1-mediated Methylation of YBX1 Promotes Tumorigenicity of Glioblastoma Stem Cells

Problem Statement
Glioblastoma (GBM) remains the most lethal primary malignant tumor of the adult central nervous system, characterized by rapid progression, diffuse infiltration, and frequent recurrence. A major barrier to effective treatment is the presence of glioblastoma stem cells (GSCs), which drive tumor heterogeneity, therapeutic resistance, and relapse. While Protein Arginine Methyltransferase 1 (PRMT1) is known to be dysregulated in glioma and associated with poor prognosis, the specific substrates and molecular mechanisms through which PRMT1 sustains GSC malignancy and tumorigenicity have remained largely undefined. Furthermore, the role of non-histone arginine methylation in regulating the multifunctional RNA-binding protein Y-box binding protein 1 (YBX1) within the context of GSCs was previously unexplored.

Methodology
The study employed a multi-faceted approach combining bioinformatics, molecular biology, and in vivo models:

• Bioinformatics and Clinical Correlation: Single-cell RNA-sequencing datasets were integrated to characterize PRMT1 expression across cell populations. Clinical relevance was assessed using the CGGA and TCGA databases, alongside immunohistochemical (IHC) analysis of 44 patient glioma tissues and 6 non-tumor controls.
• Cellular Models: Human GSC lines (GSC23, GSC11, GSC464) were utilized. Stable knockdown and overexpression models (wild-type and catalytically inactive mutants) were generated for PRMT1 and YBX1. Pharmacological inhibition was achieved using AMI-1 (PRMT1 inhibitor) and AdOx.
• Molecular Mechanisms: Co-immunoprecipitation (Co-IP), liquid chromatography-tandem mass spectrometry (LC-MS/MS), and RNA sequencing (RNA-seq) were used to identify interacting partners and downstream targets. Specific methylation sites were mapped using truncation and point mutants (e.g., YBX1-R69K). RNA stability was assessed via Actinomycin D chase experiments, and RNA-protein interactions were validated using RNA immunoprecipitation (RIP) and eCLIP-seq data integration.
• Functional Assays: In vitro proliferation (CCK-8, EdU), self-renewal (neurosphere formation, extreme limiting dilution analysis), and cell cycle analysis (flow cytometry) were performed.
• In Vivo Models: Orthotopic xenograft models in nude mice were used to assess tumor growth and survival. A cell-penetrating peptide (TAT-conjugated) targeting the YBX1 R69 methylation motif was tested for therapeutic efficacy in subcutaneous xenografts.

Key Contributions and Results

1. PRMT1 Expression and Prognosis: PRMT1 is predominantly expressed in malignant glioma cells and correlates with higher tumor grades (WHO grade 3-4), IDH wild-type status, and reduced overall survival.
2. PRMT1-YBX1 Interaction: PRMT1 physically interacts with YBX1 in the nucleus. While PRMT1 does not regulate YBX1 protein or mRNA levels, it is essential for YBX1 phosphorylation at Ser102.
3. AKT-Mediated Nuclear Translocation: PRMT1 promotes the activation of AKT (phosphorylation at Ser473), which subsequently phosphorylates YBX1 at Ser102. This phosphorylation event is required for the nuclear translocation of YBX1.
4. Identification of R69 Methylation: PRMT1 catalyzes the asymmetric dimethylation of YBX1 specifically at Arginine 69 (R69) within its cold-shock domain. This modification was confirmed using mass spectrometry, mutant analysis (R69K), and specific antibodies.
5. Functional Necessity of R69 Methylation: The methylation of YBX1 at R69 is indispensable for GSC proliferation and self-renewal. Reintroduction of wild-type YBX1 rescued the defects caused by YBX1 deletion, whereas the methylation-deficient R69K mutant failed to do so.
6. Downstream Mechanism (mRNA Stabilization): The PRMT1-YBX1 axis stabilizes the transcripts of core cell cycle genes PKMYT1 and CDCA5. PRMT1-mediated methylation at R69 enhances YBX1's binding affinity to these mRNAs (which contain m5C modifications), thereby increasing their half-life and promoting cell cycle progression. This process involves a cooperative interplay with the m5C methyltransferase NSUN2.
7. Therapeutic Intervention: A cell-penetrating peptide designed to competitively inhibit YBX1 R69 methylation effectively suppressed GSC proliferation, self-renewal, and tumor growth in xenograft models without disrupting the physical PRMT1-YBX1 interaction.
8. Clinical Validation: High levels of YBX1-R69 asymmetric dimethylation in patient tissues positively correlate with PRMT1 abundance, higher tumor grades, and poor survival outcomes.

Significance
The paper establishes a previously unreported oncogenic signaling cascade wherein PRMT1 sustains the malignant features of glioblastoma stem cells through the post-translational modification of YBX1. Specifically, PRMT1 facilitates YBX1 nuclear entry via AKT activation and catalyzes R69 methylation, which in turn stabilizes PKMYT1 and CDCA5 mRNAs to drive cell cycle progression. The study highlights that the methylation state of YBX1, rather than just its abundance, is a critical driver of tumorigenicity. Consequently, the PRMT1-YBX1 axis is identified as a promising therapeutic vulnerability. The authors propose that targeting PRMT1-dependent YBX1 arginine methylation, particularly through competitive peptide strategies, represents a novel and specific approach to inhibit GBM progression, potentially overcoming the limitations of global PRMT1 inhibition.